King's College London

Research portal

Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer

Research output: Contribution to journalArticle

P-P Wong, C. C. Yeoh, A. S. Ahmad, C. Chelala, C. Gillett, V. Speirs, J. L. Jones, H. C. Hurst

Original languageEnglish
Pages (from-to)4579-4588
Number of pages10
JournalOncogene
Volume33
Issue number37
DOIs
Publication statusPublished - 11 Sep 2014

King's Authors

Abstract

The antiestrogen tamoxifen is a well-tolerated, effective treatment for estrogen receptor-alpha-positive (ER+) breast cancer, but development of resistance eventually limits its use. Here we show that expression of MAGEA2, and related members of this cancertestis antigen family, is upregulated in tamoxifen-resistant tumor cells. Expression of MAGEA2 in tumor lines grown in vitro or as xenografts led to continued proliferation in the presence of tamoxifen. At the molecular level, we demonstrate that MAGEA2 protein localizes to the nucleus and forms complexes with p53 and ER alpha, resulting in repression of the p53 pathway but increased ER-dependent signaling. In a series of ER+, tamoxifen-treated breast cancer patients, we show a highly significant (P = 0.006) association between MAGEA (melanoma-associated antigen) expression and reduced overall survival, confirming the clinical significance of our observations.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454